Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial
Primary liver cancer, including hepatocellular carcinoma (HCC), is the fifth and second commonest cancer and cause of cancer-related mortality, respectively, worldwide.[1] HCC prognosis remains poor owing to underlying chronic liver disease, late diagnosis, and frequent recurrence-progression after treatment; many patients with HCC are diagnosed at advanced stages.[2,3]
Source: Journal of Hepatology - Category: Gastroenterology Authors: Joong-Won Park, Yoon Jun Kim, Do Young Kim, Si-Hyun Bae, Seung Woon Paik, Youn-Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong, Oh Sang Kwon, Jong Eun Yeon, Bo Hyun Kim, Jaeseok Hwang Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Urology & Nephrology